AnorMED licenses imaging technology to Bristol-Myers Squibb:
This article was originally published in Clinica
Bristol-Myers Squibb Medical Imaging has licensed technology for linking the imaging isotope technetium to a tissue-targeting agent from Vancouver, Canada-based AnorMED. BMS will use the HYNIC linker technology to develop diagnostic imaging products for cardiovascular diseases. AnorMED will receive an up-front payment of $0.1m and annual payments until 2007, as well as milestons and royalties. The same HYNIC technology has also been licensed to North American Scientific, which is developing a prognostic imaging agent for cancer and other diseases.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.